Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.92)
# 2,960
Out of 4,711 analysts
41
Total ratings
47.37%
Success rate
1.68%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $113.08 | +32.65% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $39.39 | +103.10% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $7.51 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $65.35 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $11.91 | +0.76% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $47.71 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $85.00 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $2.87 | +1,119.51% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $97.11 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $623.82 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.60 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $113.08
Upside: +32.65%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $39.39
Upside: +103.10%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $7.51
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $65.35
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $11.91
Upside: +0.76%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $47.71
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $85.00
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $2.87
Upside: +1,119.51%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $97.11
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $623.82
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $33.60
Upside: -